Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification.

MLA

Netto, George J., et al. “Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification.” European Urology, vol. 83, no. 4, Apr. 2023, pp. 301–03. EBSCOhost, https://doi.org/10.1016/j.eururo.2022.09.015.

APA

Netto, G. J., Amin, M. B., Compérat, E. M., Gill, A. J., Hartmann, A., Moch, H., Menon, S., Raspollini, M. R., Rubin, M. A., Srigley, J. R., Hoon Tan, P., Tickoo, S. K., Tsuzuki, T., Turajlic, S., Cree, I., & Berney, D. M. (2023). Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification. European Urology, 83(4), 301–303. https://doi.org/10.1016/j.eururo.2022.09.015

Chicago

Netto, George J, Mahul B Amin, Eva M Compérat, Anthony J Gill, Arndt Hartmann, Holger Moch, Santosh Menon, et al. 2023. “Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification.” European Urology 83 (4): 301–3. doi:10.1016/j.eururo.2022.09.015.